Tuesday, 24 April 2018 - 9:49
  • it
  • de
  • en
  • fr

M&A

Fresenius abandons $4.3bn acquisition of Akorn

Fresenius has announced today what everyone dreaded. The Bad Homburg (Frankfurt)-based group has informed in a press release it will terminate the program to acquire the US-based Akorn. Fresenius has stated that there are no guarantees for an acquisition, since…

Wacker acquires biopharmaceuticals site in Luxembourg

The Germany-based chemical group Wacker Chemie AG has acquired a Dutch site for manufacturing vaccines and microbial products from Luxembourg-based SynCo. The plants’ high output–thanks to two fermentation lines with capacities of 1,500 and 270 liters, will allow Wacker to…

Sanofi sells 12 drugs to Cooper-Vemedia for €158m

The Belgian daily der Standard has reported that Sanofi has sold 12 brands to Cooper-Vemedia for €158m. The sale is part of Sanofi’s strategy to simplify its product portfolio and fund its recent acquisitions. Cooper-Vemedia belongs to private equity Charterhouse…

Advent offers €1.919bn for Sanofi’s Zentiva

Private equity Advent International has announced today in a press release that it is in exclusive talks with Sanofi to acquire Zentiva, the French company’s arm that markets generics all over Europe. Advent has offered Sanofi €1.919bn. Advent International, which…

Advent Capital now about to acquire Sanofi’s Zentiva ($2bn)

Advent International is reportedly about to acquire Zentiva, Sanofi’s European arm marketing generics. Advent has beaten its competitor, the investor BC Partners, the Financial Times has reported. Private equities Blackstone and Nordic Capital have already pulled out from the race…

GSK announces sale of rare disease therapies to Orchard Therapeutics

GlaxoSmithKline has sold its rare disease therapy portfolio to Orchard Therapeutics in exchange for 20% of shares in the Anglo-American biotech and royalties on profits delivered by Orchard with GSK’s treatments. GSK’s move allows the UK-based company to focus on…

Ionis sells NASH therapy to AstraZeneca for $300m

California-based Ionis Pharmaceuticals has announced it has licensed to AstraZeneca its investigational therapy Ionis-AZ6-2.5, developed to treat patients with Non-Alcoholic Steatohepatitis (NASH). This is the third therapy obtained from the partnership between the firms. Under the terms of the agreement,…

Novartis acquires AveXis for $8.7bn

Novartis has announced it has acquired AveXis for $8.7bn, paying it $218 per share, that is a 88% premium over the company’s closing price on Friday ($115.9). AveXis focuses on gene therapies for the treatment of spinal muscular atrophy and…

Switzerland’s Ferring Pharmaceuticals acquires Rebiotix

Switzerland-based Ferring Pharmaceuticals has announced today that it has acquired Minnesota, US-based Rebiotix, a company focusing on the development of new treatments by obtaining information from patients’ microbiome. The main asset of the acquired company is undoubtedly RBX2660, a new…

GE sells part of GE Healthcare to private equity ($1.05bn)

General Electric has sold its Enterprise Financial Management, Ambulatory Care Management and Workforce Management to private equity Veritas for $1.05bn. The assets belong to GE Healthcare and provide software to companies focusing on Healthcare. GE Healthcare is one of the…

P&G targeting Pfizer’s Consumer Health arm

CNBC yesterday afternoon reported that the US giant Procter & Gamble is in talks with Pfizer to acquire the company’s Consumer Health arm. P&G, in fact, is the only potential buyer left, after Reckitt Benckiser and GlaxoSmithKline have announced they…

Fujifilm aggressive in biotech sector again: acquires two companies for $800m

Fujifilm announced today as trading closed that it has acquired for approximately $800m two companies specialized in cultured cells, subsidiaries of Japanese holding JXTG.  Specifically, the two companies are the California-based Irvine Scientific (ISUS) and the Japan-based IS Japan (ISJ),…

Mankind Pharma sells 10% stake to fund for $350m

Mankind Pharma has sold 10% of its shares to the investment fund ChrysCapital for approximately $350m (INR22.8bn), reaching an approximate value of  $3.5bn, which meets analysts’ expectations. Shares of the New Delhi-based company are currently held by the Juneja family…

Battle to acquire GlaxoSmithKline’s Horlicks has started

Livemint has reported today that Switzerland-based Nestlé, US-based   Kraft Heinz and Unilever and India-based ITC are the potential buyers of GlaxoSmithKline’s Horlicks asset. Horlicks is one of the most important of GSK’s brands and is likely to be sold for…

Novartis sells GSK its share in JV Consumer Health for $13bn

Novartis and GlaxoSmithKline have jointly announced today, before trading opened in Europe, that GSK has sold 36.5% of JV Consumer Health’s shares to GSK for $13bn. The deal allows GSK to secure one of the largest Consumer Health divisions in…

M&A of Consumer Health units at a stalemate

The market provides with a wide range of opportunities those companies that want to enhance their Consumer Health portfolio through acquisitions. Assets are currently on sale by Germany-based Merck KGaA, intending to dismiss its Consumer Health arm for €4bn, and…

GSK as well renounces to acquire Pfizer’s Consumer Health arm

GlaxoSmithKline informed this morning in a short, concise press release that it will pull out of the process to acquire Pfizer’s Consumer Health division. CEO Emma Walmsley added that the group will keep reviewing other opportunities consistent with its strategy,…

European competition watchdog approves $66bn Bayer-Monsanto agreement

Bayer has been granted approval to the $66bn acquisition of Monsanto by the European antitrust authorities. The approval is subject to Bayer selling part of its assets–seeds and herbicides–to competitor BASF. Additionally, Bayer has committed to the European Commission to…

Fresenius keeps expanding in South America: 2 clinics acquired

Germany-based Fresenius seems unstoppable and determined to grow in South America through takeovers. The Brazilian financial portal Valor Economico has reported today that Fresenius has acquired Medservi and Unidade de Dialise de Transplante, two clinics for dialysis. Both companies are…

Three groups targeting Orchid Pharma’s assets

The Economic Times has reported today that three companies have stepped forward to acquire the assets of India-based Orchid Pharma, currently in bankruptcy proceedings and with a debt of as much as INR35bn ($537m). The three bids have been submitted…

Lundbeck acquires Netherlands-based Prexton Therapeutics for €955m

Denmark-based Lundbeck A/S has announced today it has acquired Netherlands-based Prexton Therapeutics BV for €955m. Specifically, the agreement includes an upfront €100m payment, plus an additional €805m if Prexton reaches precise commercial targets. Prexton’s main asset is probably foliglurax, a…

First offer ($2.1bn) for J&J’s LifeScan

Platinum Equity, a private equity with $ 13 billion of assets, has submitted a $2.1bn offer to the US-based group Johnson & Johnson  for its LifeScan arm, focused on the diabetes area. The LifeScan unit, headquartered in Chesterbrook (Pennsylvania) and…

Stada could now target Hikma

German generics manufacturer Stada could target competitor Hikma, according to a statement by CEO Claudio Albrecht reported by The Sunday Telegraph. Albrecht has reportedly said that his company is seeking acquisitions and is targeting UK companies. The two most likely…

Oncology business to keep dominating M&A scene in 2018

2017 was an outstanding year for M&A in pharma. The most significant deals were clearly JnJ’s $30bn acquisition of Actelion and Gilead’s $11.9bn acquisition of Kite . Therefore, a new spate of acquisitions is expected for 2018. One of the…